{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:32:27Z","timestamp":1795026747713,"version":"4.10.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Metastatic uveal melanoma (mUM) has a poor prognosis, with liver metastases typically presenting a therapeutic challenge. Melphalan\/Hepatic Delivery System (Melphalan\/HDS) is a drug\/medical device combination used for liver-directed treatment of unresectable mUM patients. This study assessed efficacy and safety of Melphalan\/HDS versus best alternative care (BAC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Eligible patients with unresectable mUM were randomized (1:1) to receive Melphalan\/HDS (3 mg\/kg ideal body weight) once every 6\u00a0to\u00a08 weeks for a maximum of 6 cycles or BAC. Due to slow enrollment and patient reluctance to receive BAC treatment, the\u00a0study design was amended to a single-arm Melphalan\/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study enrolled 85 patients.\u00a0Eligible patients were randomized to receive Melphalan\/HDS (<jats:italic>n<\/jats:italic> = 43) or BAC (<jats:italic>n<\/jats:italic> = 42), and 72 patients received study treatment (Melphalan\/HDS [<jats:italic>n<\/jats:italic> = 40]; BAC [<jats:italic>n<\/jats:italic> = 32]). Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan\/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%). Serious adverse events (SAEs) occurred in 51.2% of Melphalan\/HDS and in 21.9% of BAC patients. The\u00a0most common (&gt;5%) SAEs included thrombocytopenia (19.5%), neutropenia (9.8%), leukopenia (9.8%) and febrile neutropenia (7.3%) in Melphalan\/HDS patients and cholecystitis, nausea and vomiting (6.3% each) in BAC patients. No treatment-related deaths were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Treatment with Melphalan\/HDS shows clinically meaningful efficacy and demonstrates a favorable benefit-risk profile in patients with unresectable mUM as compared to BAC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17231-x","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T08:04:51Z","timestamp":1744099491000},"page":"4976-4988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["An Open-label, Randomized Study of Melphalan\/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6886-4468","authenticated-orcid":false,"given":"Jonathan S.","family":"Zager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlana","family":"Orloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Francesco","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Eschelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Glazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslam","family":"Ejaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Harrison","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Richtig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil A.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gschnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Rivoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen William","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Weishaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wheater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Ottensmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"2","key":"17231_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","volume":"20","author":"RD Carvajal","year":"2023","unstructured":"Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Bagge RO, Harbour JW, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20(2):99\u2013115. https:\/\/doi.org\/10.1038\/s41571-022-00714-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"17231_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala ES, Hernberg M, Kivel\u00e4 TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000575.","journal-title":"Melanoma Res"},{"issue":"8","key":"17231_CR3","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370\u201380. https:\/\/doi.org\/10.1093\/annonc\/mdz176.","journal-title":"Ann Oncol"},{"issue":"9","key":"17231_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaophthalmol.2018.2466","volume":"136","author":"AM Lane","year":"2018","unstructured":"Lane AM, Kim IK, Gragoudas ES. Survival rates in patients after treatment for metastasis from uveal melanoma. JAMA Ophthalmol. 2018;136(9):981\u20136. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.2466.","journal-title":"JAMA Ophthalmol"},{"issue":"13","key":"17231_CR5","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"issue":"13","key":"17231_CR6","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.3390\/cancers13133359","volume":"13","author":"EA Koch","year":"2021","unstructured":"Koch EA, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, et al. Immune checkpoint blockade for metastatic uveal melanoma: Patterns of response and survival according to the presence of hepatic and extrahepatic metastasis. Cancers (Basel). 2021;13(13):3359. https:\/\/doi.org\/10.3390\/cancers13133359.","journal-title":"Cancers (Basel)"},{"key":"17231_CR7","doi-asserted-by":"publisher","first-page":"1908065","DOI":"10.1155\/2018\/1908065","volume":"2018","author":"C Mignard","year":"2018","unstructured":"Mignard C, Huvier AD, Gillibert A, Modeste ABD, Dutriaux C, Khammari A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. J Oncol. 2018;2018:1908065. https:\/\/doi.org\/10.1155\/2018\/1908065.","journal-title":"J Oncol"},{"issue":"1","key":"17231_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000331","volume":"8","author":"YG Najjar","year":"2020","unstructured":"Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8(1):e000331. https:\/\/doi.org\/10.1136\/jitc-2019-000331.","journal-title":"J Immunother Cancer"},{"issue":"21","key":"17231_CR9","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344\u201353. https:\/\/doi.org\/10.1002\/cncr.30258.","journal-title":"Cancer"},{"issue":"6","key":"17231_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39(6):599\u2013607. https:\/\/doi.org\/10.1200\/JCO.20.00605.","journal-title":"J Clin Oncol"},{"issue":"6","key":"17231_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.20.00550","volume":"39","author":"JM Piulats","year":"2021","unstructured":"Piulats JM, Espinosa E, Merino LC, Varela M, Carrion LA, Martin-Algarra S, et al. Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39(6):586\u201398. https:\/\/doi.org\/10.1200\/JCO.20.00550.","journal-title":"J Clin Oncol"},{"issue":"4","key":"17231_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/CMR.0000000000000900","volume":"33","author":"JP Pham","year":"2023","unstructured":"Pham JP, On L, Ardolino L, Hurwitz J, Salaun H, Sim H-W, et al. Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2023;33(4):316\u201325. https:\/\/doi.org\/10.1097\/CMR.0000000000000900.","journal-title":"Melanoma Res"},{"issue":"3","key":"17231_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/s0197-2456(01)00113-1","volume":"22","author":"CS Moy","year":"2001","unstructured":"Moy CS, Albert DM, Diener-West M, McCaffrey LD, Scully RE, Wilson JK, et al. Cause-specific mortality coding: methods in the collaborative ocular melanoma study COMS report no. 14. Control Clin Trials. 2001;22(3):248\u201362. https:\/\/doi.org\/10.1016\/s0197-2456(01)00113-1.","journal-title":"Control Clin Trials"},{"key":"17231_CR14","unstructured":"National Comprehensive Cancer Network (NCCN 2022). NCCN clinical practice guidelines in oncology for melanoma: uveal. Version 2.2022. Available at https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1488 (Accessed May 21, 2024)."},{"key":"17231_CR15","unstructured":"National Institute for Health and Care Excellence (NICE) guidance. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. Available at https:\/\/www.nice.org.uk\/guidance\/ipg691 (Accessed May 21, 2024)."},{"key":"17231_CR16","unstructured":"HEPZATO KIT Hepatic Delivery System. US Food and drug administration prescribing information Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/201848s000lbl.pdf (Accessed May 21, 2024)."},{"issue":"8","key":"17231_CR17","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.3390\/cancers13184726","volume":"13","author":"MS Bethlehem","year":"2021","unstructured":"Bethlehem MS, Katsarelias D, Bagge RO. Meta-analysis of isolated hepatic perfusion and percutaneous hepatic perfusion as a treatment for uveal melanoma liver metastases. Cancers (Basel). 2021;13(8):4726. https:\/\/doi.org\/10.3390\/cancers13184726.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"17231_CR18","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.22.01705","volume":"41","author":"RO Bagge","year":"2023","unstructured":"Bagge RO, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, et al. Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial). J Clin Oncol. 2023;41(16):3042\u201350. https:\/\/doi.org\/10.1200\/JCO.22.01705.","journal-title":"J Clin Oncol"},{"issue":"2","key":"17231_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/CMR.0000000000000806","volume":"32","author":"S Modi","year":"2022","unstructured":"Modi S, Gibson T, Vigneswaran G, Patel S, Wheater M, Karydis I, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Res. 2022;32(2):103\u201311. https:\/\/doi.org\/10.1097\/CMR.0000000000000806.","journal-title":"Melanoma Res"},{"key":"17231_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","volume":"28","author":"TS Meijer","year":"2021","unstructured":"Meijer TS, Burgmans MC, de Leede EM, de Geus-Oei L-F, Boekestijin B, Handgraaf HJM, et al. Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study. Ann Surg Oncol. 2021;28:1130\u201341. https:\/\/doi.org\/10.1245\/s10434-020-08741-x.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"17231_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00270-015-1276-z","volume":"39","author":"MC Burgmans","year":"2016","unstructured":"Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol. 2016;39(6):801\u201314. https:\/\/doi.org\/10.1007\/s00270-015-1276-z.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"17231_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","volume":"19","author":"C Artzner","year":"2019","unstructured":"Artzner C, Mossakowski O, Hefferman G, Grosse U, Hoffmann R, Forschner A, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging. 2019;19:31. https:\/\/doi.org\/10.1186\/s40644-019-0218-4.","journal-title":"Cancer Imaging"},{"issue":"1","key":"17231_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/cancers14010118","volume":"14","author":"CLA Dewald","year":"2022","unstructured":"Dewald CLA, Warnke MM, Br\u00fcning R, Schneider MA, Wohlmuth P, Hinrichs JB, et al. Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the German experience. Cancers (Basel). 2022;14(1):118. https:\/\/doi.org\/10.3390\/cancers14010118.","journal-title":"Cancers (Basel)"},{"key":"17231_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"17231_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"17231_CR26","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services: National Institutes of Health, National Cancer Institute. Available at: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (Accessed May 21, 2024)."},{"key":"17231_CR27","unstructured":"KIMMTRAK (tebentafusp-tebn). US Food and drug administration prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761228s000lbl.pdf (Accessed May 21, 2024)."},{"issue":"2","key":"17231_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.18240\/ijo.2023.02.18","volume":"16","author":"YX Tao","year":"2023","unstructured":"Tao YX, Li HW, Luo JT, Li Y, Wei W-B, et al. Regional chemotherapy for uveal melanoma liver metastases. Int J Ophthalmol. 2023;16(2):293\u2013300. https:\/\/doi.org\/10.18240\/ijo.2023.02.18.","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"17231_CR29","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/annonc\/mdt585","volume":"25","author":"S Leyvraz","year":"2014","unstructured":"Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol. 2014;25(3):742\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdt585.","journal-title":"Ann Oncol"},{"issue":"4","key":"17231_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","volume":"26","author":"ME Valsecchi","year":"2015","unstructured":"Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva I, Shields JA, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol. 2015;26(4):523-32.e2. https:\/\/doi.org\/10.1016\/j.jvir.2014.11.037.","journal-title":"J Vasc Interv Radiol"},{"issue":"8","key":"17231_CR31","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","volume":"40","author":"EM de Leede","year":"2017","unstructured":"de Leede EM, Burgmans MC, Meijer TS, Martini CH, Tijl FGJ, Vuyk J, et al. Prospective clinical and pharmacological evaluation of the Delcath system\u2019s second-generation (GEN2) hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan. Cardiovasc Intervent Radiol. 2017;40(8):1196\u2013205. https:\/\/doi.org\/10.1007\/s00270-017-1630-4.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"17231_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00270-019-02177-x","volume":"42","author":"TS Meijer","year":"2019","unstructured":"Meijer TS, Burgmans MC, Fiocco M, de Geus-Oei L-F, Kapitejin E, de Leede EM, et al. Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath Systems\u2019 second-generation hemofiltration system: a prospective non-randomized phase II trial. Cardiovasc Intervent Radiol. 2019;42(6):841\u201352. https:\/\/doi.org\/10.1007\/s00270-019-02177-x.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"17231_CR33","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00270-022-03225-9","volume":"45","author":"TML Tong","year":"2022","unstructured":"Tong TML, Samim M, Kapiteijn E, Meijer TS, Speetjens FM, Br\u00fcning R, et al. Predictive parameters in patients undergoing percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma: a retrospective pooled analysis. Cardiovasc Intervent Radiol. 2022;45(9):1304\u201313. https:\/\/doi.org\/10.1007\/s00270-022-03225-9.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"17231_CR34","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00270-022-03338-1","volume":"46","author":"TML Tong","year":"2023","unstructured":"Tong TML, Burgmans MC, Speetjens FM, van Erkel AR, Meer RW, et al. Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: first safety and efficacy data from the phase Ib part of the Chopin trial. Cardiovasc Intervent Radiol. 2023;46(3):350\u20139. https:\/\/doi.org\/10.1007\/s00270-022-03338-1.","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17231-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:58:07Z","timestamp":1748869087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17231-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["17231"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17231-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JZ\u2013global principal investigator in the FOCUS phase 3 study and serves on Delcath Systems Medical Advisory Board. Education and Training grant through Delcath. Has consulting agreements and\/or participated on advisory board panels with Merit Medical, Replumune, Merck, Philogen, Castle Biosciences and Menarini Silicon Biosystems.\u00a0MO\u2013Advisory Board: Delcath, Replimune. Consultant: Immunocore. Steering Committee: Ideaya. Speaker: Immunocore. DE\u2013Consulting fees from Delcath. EG\u2013Institutional funding for conducting the Phase 3 FOCUS study. JH\u2013Consultant: Delcath. ER\u2013Medical University of Graz received payments for conducting the Phase 3 FOCUS study. SO\u2013Advice: Immunocore, Delcath, Janssen. Speakers\u2019 bureau: Immunocore. Honoraria for presentations: MSD, AstraZeneca, Merck; Travel funding: Merck, Pfizer, Ipsen. GB\u2013Clinical trial funding paid to institution from Replimune, Checkmate pharmaceuticals, Philogen, Delcath. Advisory board: BMS. AG\u2013University Hospital W\u00fcrzburg received institutional\u00a0payments for conducting the Phase 3 FOCUS study. RD\u2013Consulting and\/or advisory relationships with Novartis, Merck Sharp & Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer, Simcere and touchIME. AA\u2013Consulting or advisory role: Pierre Fabre, Novartis, Roche, BMS, MSD, Biontech. Speakers\u2019 Bureau: Pierre Fabre, Novartis, Roche, BMS, MSD. Travel, Accommodations, Expenses: BMS, MSD. SF\u2013Liverpool University Hospitals NHS Trust received institutional\u00a0support for conducting this Phase 3 FOCUS study from the trial sponsor. JS\u2013Advisory boards: Delcath, Replimune and Immunocore. Grant funding: Astra Zeneca and BMS (paid to institution). Travel and conference attendance: MSD, BMS and Replimune. SH - Speakers Honoraria: BMS, MSD, Pierre Fabre, Sanofi, Immunocore.\u00a0MW\u2013Institutional (University Hospital Southampton) funding for conducting a commercial trial. Personal funding for participation in advisory board for Delcath. JJ\u2013Employee of Delcath.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}